Europe Injectable Drug Delivery Devices Market - Growth, Trends, and Forecast (2020 - 2025)

The market is segmented By Devices Type (Conventional Drug Delivery Devices and Self-injectable Drug Delivery Devices), Therapeutic Application, and Geography

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

CAGR:

10.5 %

Major Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Injectable drug delivery is used in various conditions, such as hormonal imbalance, autoimmune diseases, pain, hemophilia etc. The self-administration of medications is growing rapidly, with flexible assembled pens and self-injectors giving patients a sense of autonomy and usage flexibility. These injections are also becoming the choice of pharmaceutical companies, device manufacturers, and patients, due to the advantages of self-administration, and use of fixed doses. These devices are focused on ease of use, patient comfort, and compliance. The adoption of self injectors has thus reduced the number of medical appointments, and patients gain more flexibility and convenience in their daily life, which is expected to drive the market growth over the forecast period.

Scope of the report

As per the scope of the report, the injectable devices are being used to administer drugs either intravenously, through intramuscular, or subcutaneously, and are considered as injectable drug delivery devices. 

By Devices Type
Conventional Drug Delivery Devices
Self-injectable Drug Delivery Devices
Prefilled Syringes
Injectable Pens
Auto Injectors
Needle-free Injectors
Other Device Types
By Therapeutic Application
Cardiovascular Disease
Diabetes
Oncology
Autoimmune Disorders
Hepatitis
Other Therapeutic Applications
Geography
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe

Report scope can be customized per your requirements. Click here.

Key Market Trends

Self-injectable Drug Delivery Devices Segment is Expected to Show Better Growth in the Forecast Years

Based on Device type, the market is segmented into conventional drug delivery devices and self-injectable drug delivery devices. The major factor attributed to the high growth of the segment is the growing burden of chronic disease and the convenience associated with the device. The acceptance of these products has increased over the past few years owing to the advantages of self-injectable injections and increasing awareness of self-administration. Many global and domestic companies have expanded their portfolios in this field, resulting in new and innovative solutions. For instance, in 2019, BIOCORP, has presented its new innovative device that allows any pre-filled syringe to evolve into a connected device. Hence, owing to these factors, the market is expected to grow in the forecast years.

To understand key trends, Download Sample Report

Competitive Landscape

The market studied  is moderately competitive and most of the companies are international players. The major players in Europe injectable drug delivery devices market are Baxter International, Becton, Dickinson and Company, Eli Lilly and Company, Gerresheimer AG, Novo Nordisk, Pfizer, Schott AG, Terumo Corporation, Teva Pharmaceutical Industries and West Pharmaceutical Services Inc.

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Chronic Diseases

      2. 4.2.2 Benefits and Convenience Offered by Self Injectors

    3. 4.3 Market Restraints

      1. 4.3.1 Injuries and Infections Caused by Needles

      2. 4.3.2 Growing Use of Alternative Delivery Methods

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Devices Type

      1. 5.1.1 Conventional Drug Delivery Devices

      2. 5.1.2 Self-injectable Drug Delivery Devices

        1. 5.1.2.1 Prefilled Syringes

        2. 5.1.2.2 Injectable Pens

        3. 5.1.2.3 Auto Injectors

        4. 5.1.2.4 Needle-free Injectors

        5. 5.1.2.5 Other Device Types

    2. 5.2 By Therapeutic Application

      1. 5.2.1 Cardiovascular Disease

      2. 5.2.2 Diabetes

      3. 5.2.3 Oncology

      4. 5.2.4 Autoimmune Disorders

      5. 5.2.5 Hepatitis

      6. 5.2.6 Other Therapeutic Applications

    3. 5.3 Geography

      1. 5.3.1 Europe

        1. 5.3.1.1 Germany

        2. 5.3.1.2 United Kingdom

        3. 5.3.1.3 France

        4. 5.3.1.4 Italy

        5. 5.3.1.5 Spain

        6. 5.3.1.6 Rest of Europe

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Baxter International Inc.

      2. 6.1.2 Becton, Dickinson and Company

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 Gerresheimer AG

      5. 6.1.5 Novo Nordisk A/S

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Schott AG

      8. 6.1.8 Terumo Corporation

      9. 6.1.9 Teva Pharmaceutical Industries Ltd

      10. 6.1.10 West Pharmaceutical Services Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

Related Reports